News brief­ing: Ex­elix­is pays $20M to in-li­cense a pre­clin­i­cal ADC for the pipeline; An­oth­er pre­clin­i­cal biotech shoots for a big IPO

Eigh­teen months af­ter Ex­elix­is signed on to part­ner with Icon­ic Ther­a­peu­tics on an an­ti­body-drug con­ju­gate, more mon­ey is flow­ing.

Ex­elix­is is pick­ing up its ex­clu­sive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER